Lytix Biopharma AS
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
LYTIX | OL
Overview
Corporate Details
- ISIN(s):
- NO0010405780
- LEI:
- 549300NXMIMRSBCDZO71
- Country:
- Norway
- Address:
- Sandakerveien 138, 0484 OSLO
- Website:
- https://www.lytixbiopharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lytix Biopharma AS is a clinical-stage immuno-oncology company developing novel cancer immunotherapies based on its proprietary technology platform. The platform utilizes host-defense peptide-derived molecules engineered to kill cancer cells and stimulate a targeted anti-tumor immune response. The company's lead product candidate, LTX-315, is an oncolytic peptide being evaluated in various clinical trials, including for Basal Cell Carcinoma. Lytix's therapeutic agents are designed for use as monotherapies and in combination with other treatments, such as checkpoint inhibitors and cell therapies, to enhance their efficacy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 642.2 KB | ||
| 2025-08-28 07:00 |
Investor Presentation
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 2.7 MB | ||
| 2025-08-28 07:00 |
Interim Report
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 1.1 MB | ||
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 4.9 KB | ||
| 2025-08-21 13:53 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q2 2025 Results Presentation - Attachment: Lytix…
|
English | 611.2 KB | ||
| 2025-08-21 13:53 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q2 2025 Results Presentation
|
English | 1.9 KB | ||
| 2025-05-21 14:05 |
Director's Dealing
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
|
English | 223.9 KB | ||
| 2025-05-21 14:05 |
Remuneration Information
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
|
English | 2.2 KB | ||
| 2025-05-15 05:00 |
Investor Presentation
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phas…
|
English | 2.8 MB | ||
| 2025-05-15 05:00 |
Earnings Release
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phas…
|
English | 5.4 KB | ||
| 2025-05-09 05:00 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
|
English | 129.9 KB | ||
| 2025-05-09 05:00 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
|
English | 2.0 KB | ||
| 2025-04-29 12:19 |
Post-Annual General Meeting Information
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New B…
|
Norwegian | 172.5 KB | ||
| 2025-04-29 12:19 |
Post-Annual General Meeting Information
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New B…
|
English | 4.3 KB | ||
| 2025-04-22 19:18 |
Board/Management Information
Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committ…
|
English | 164.6 KB |
Automate Your Workflow. Get a real-time feed of all Lytix Biopharma AS filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Lytix Biopharma AS via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
